Celcuity (CELC) stock was up more than 113% pre-bell Monday after the company said results from a phase 3 trial showed that a combination of gedatolisib, palbociclib, and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone in patients with locally advanced or metastatic breast cancer.
Mill City Ventures III (MCVT) shares were 61% higher, extending Friday's rally.
TruGolf (TRUG) stock was up 22% following a 5.8% loss on Friday.
22nd Century Group (XXII) shares were 23% higher, adding to a 4.1% increase in the previous session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.